No label defined (Q28255051)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	No label defined	scientific article

Statements

scholarly article

0 references

Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment (English)

0 references

0 references

multiple sclerosis

0 references

author name string

K G Warren

1

0 references

I Catz

2

0 references

L Z Ferenczi

3

0 references

M J Krantz

4

0 references

language of work or name

0 references

publication date

August 2006

0 references

European Journal of Neurology

0 references

13

0 references

8

0 references

887-95

0 references

Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event

1 reference

https://api.crossref.org/works/10.1111/J.1468-1331.2006.01533.X

21 April 2017

Multiple sclerosis: the disease and its manifestations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01533.X

21 January 2018

Key issues in the diagnosis and treatment of multiple sclerosis. An overview

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01533.X

21 January 2018

Effective antigen-specific immunotherapy in the marmoset model of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01533.X

21 January 2018

Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01533.X

21 January 2018

Cerebrospinal fluid autoantibodies to myelin basic protein in multiple sclerosis patients. Detection during first exacerbations and kinetics of acute relapses and subsequent convalescent phases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01533.X

21 January 2018

B cells and antibodies in CNS demyelinating disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01533.X

21 January 2018

Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01533.X

21 January 2018

T-cell recognition of myelin basic protein

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01533.X

21 January 2018

Increased synthetic peptide specificity of tissue-CSF bound anti-MBP in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01533.X

21 January 2018

Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01533.X

21 January 2018

Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01533.X

21 January 2018

Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01533.X

21 January 2018

The effect of intrathecal MBP synthetic peptides containing epitope P85 VVHFFKNIVTP96 on free anti-MBP levels in acute relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01533.X

21 January 2018

Kinetic profiles of cerebrospinal fluid anti-MBP in response to intravenous MBP synthetic peptide DENP(85)VVHFFKNIVTP(96)RT in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01533.X

21 January 2018

Antigen-specific immunomodulation via altered peptide ligands

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01533.X

21 January 2018

A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01533.X

21 January 2018

Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin antigens: IV. Suppression of chronic relapsing disease in the lewis rat and strain 13 guinea pig

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01533.X

21 January 2018

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01533.X

21 January 2018

T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01533.X

21 January 2018

Identifiers

10.1111/J.1468-1331.2006.01533.X

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28255051&oldid=1962050851"